Williams Paul
Life Sciences, Lawrence Berkeley National Laboratory, Berkeley, USA.
Cureus. 2023 Sep 11;15(9):e45054. doi: 10.7759/cureus.45054. eCollection 2023 Sep.
The best overall measure of kidney function is glomerular filtration rate (GFR) as commonly estimated from serum creatinine concentrations (eGFR) using formulas that correct for the higher average creatinine concentrations in Blacks. After two decades of use, these formulas have come under scrutiny for estimating GFR differently in Blacks and non-Blacks. Discussions of whether to include race (Black vs. non-Black) in the calculation of eGFR fail to acknowledge that the original race-based eGFR provided the same CKD treatment recommendations for Blacks and non-Blacks based on directly (exogenously) measured GFR. Nevertheless, the and the removed race in CKD treatment guidelines and pushed for the immediate adoption of a race-free eGFR formula by physicians and clinical laboratories. This formula is projected to negate CKD in 5.51 million White and other non-Black adults and reclassify CKD to less severe stages in another 4.59 million non-Blacks, in order to expand treatment eligibility to 434,000 Blacks not previously diagnosed and to 584,000 Blacks previously diagnosed with less severe CKD. This review examines: 1) the validity of the arguments for removing the original race correction, and 2) the performance of the proposed replacement formula. Excluding race in the derivation of eGFR changed the statistical bias from +3.7 to -3.6 ml/min/1.73m in Blacks and from +0.5 to +3.9 in non-Blacks, i.e., promoting CKD diagnosis in Blacks at the cost of restricting diagnosis in non-Blacks. By doing so, the revised eGFR greatly exaggerates the purported racial disparity in CKD burden. Claims that the revised formulas identify heretofore undiagnosed CKD in Blacks are not supported when studies that used kidney failure replacement therapy and mortality are interpreted as proxies for baseline CKD. Alternatively, a race-stratified eGFR (i.e., separate equations for Blacks and non-Blacks) would provide the least biased eGFR for both Blacks and non-Blacks and the best medical treatment for all patients.
评估肾功能的最佳综合指标是肾小球滤过率(GFR),通常根据血清肌酐浓度(eGFR),使用针对黑人较高平均肌酐浓度进行校正的公式来估算。经过二十年的使用,这些公式因在黑人与非黑人中估算GFR的方式不同而受到审视。关于是否将种族(黑人与非黑人)纳入eGFR计算的讨论,没有认识到最初基于种族的eGFR根据直接(外源性)测量的GFR为黑人和非黑人提供了相同的CKD治疗建议。尽管如此,[具体机构1]和[具体机构2]在CKD治疗指南中取消了种族因素,并敦促医生和临床实验室立即采用无种族的eGFR公式。预计该公式将使551万白人及其他非黑人成年人的CKD被否定,并使另外459万非黑人的CKD重新分类为较轻阶段,以便将治疗资格扩大到43.4万以前未被诊断出的黑人以及58.4万以前被诊断为较轻CKD的黑人。本综述探讨了:1)取消原种族校正论点的有效性,以及2)提议的替代公式的性能。在推导eGFR时排除种族因素,使黑人的统计偏差从+3.7变为-3.6 ml/min/1.73m²,非黑人从+0.5变为+3.9,即以限制非黑人诊断为代价促进黑人的CKD诊断。这样做,修订后的eGFR极大地夸大了所谓的CKD负担的种族差异。当将使用肾衰竭替代疗法和死亡率的研究解释为基线CKD的替代指标时,关于修订后的公式能识别出黑人中迄今未被诊断出的CKD的说法是没有依据的。或者,按种族分层的eGFR(即黑人和非黑人分别使用不同方程)将为黑人和非黑人提供偏差最小的eGFR,并为所有患者提供最佳医疗治疗。